Veradermics, Incorporated (MANE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Veradermics, Incorporated (MANE) has a cash flow conversion efficiency ratio of -0.054x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.17 Million) by net assets ($391.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MANE equity financing ratio to measure how much of total assets are equity-financed.
Veradermics, Incorporated - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Veradermics, Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Veradermics, Incorporated debt service capacity to assess how comfortably operating cash covers total debt obligations.
Veradermics, Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Veradermics, Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Changzhou Xingyu Automotive Lighting Systems Co Ltd
SHG:601799
|
0.059x |
|
Allete Inc
NYSE:ALE
|
0.031x |
|
Trex Company Inc
NYSE:TREX
|
-0.119x |
|
Rogers Communications Inc
TO:RCI-A
|
0.061x |
|
CVB Financial Corporation
NASDAQ:CVBF
|
0.027x |
|
Xinjiang Tianshan Cement Co Ltd
SHE:000877
|
0.033x |
|
Beta Technologies, Inc.
NYSE:BETA
|
-0.055x |
|
Guangzhou Haige Communications Group Incorporated Co
SHE:002465
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Veradermics, Incorporated (2023–2025)
The table below shows the annual cash flow conversion efficiency of Veradermics, Incorporated from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see MANE market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-121.01 Million | $-71.60 Million | 0.592x | +236.54% |
| 2024-12-31 | $54.66 Million | $-23.69 Million | -0.433x | +53.11% |
| 2023-12-31 | $14.62 Million | $-13.51 Million | -0.924x | -- |
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in t… Read more